Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Mural Oncology plc stock logo
MURA
Mural Oncology
$2.64
+0.8%
$2.15
$0.95
$4.74
$45.59M3.911.31 million shs61,977 shs
Neuphoria Therapeutics Inc. - Common Stock stock logo
NEUP
Neuphoria Therapeutics Inc. - Common Stock
$6.48
-0.6%
$5.32
$2.12
$12.72
$12.18M0.26347,313 shs5,700 shs
OS Therapies Inc stock logo
OSTX
OS Therapies
$1.58
-7.1%
$1.62
$1.12
$7.00
$44.40MN/A471,525 shs385,710 shs
PMV Pharmaceuticals, Inc. stock logo
PMVP
PMV Pharmaceuticals
$0.90
-0.5%
$0.97
$0.81
$1.85
$46.52M1.5233,318 shs102,449 shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Mural Oncology plc stock logo
MURA
Mural Oncology
+0.76%-4.00%+0.76%-28.26%-21.19%
Neuphoria Therapeutics Inc. - Common Stock stock logo
NEUP
Neuphoria Therapeutics Inc. - Common Stock
-0.61%+4.01%+25.34%+24.62%+647,999,900.00%
OS Therapies Inc stock logo
OSTX
OS Therapies
-7.06%+3.27%-21.00%-4.24%+157,999,900.00%
PMV Pharmaceuticals, Inc. stock logo
PMVP
PMV Pharmaceuticals
-0.52%-0.51%-10.46%-34.64%-50.26%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Mural Oncology plc stock logo
MURA
Mural Oncology
3.2432 of 5 stars
3.35.00.00.02.41.71.3
Neuphoria Therapeutics Inc. - Common Stock stock logo
NEUP
Neuphoria Therapeutics Inc. - Common Stock
1.6233 of 5 stars
3.50.00.00.02.20.00.6
OS Therapies Inc stock logo
OSTX
OS Therapies
1.8026 of 5 stars
3.70.00.00.00.61.70.6
PMV Pharmaceuticals, Inc. stock logo
PMVP
PMV Pharmaceuticals
2.8285 of 5 stars
3.53.00.00.03.51.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Mural Oncology plc stock logo
MURA
Mural Oncology
2.60
Moderate Buy$13.00392.42% Upside
Neuphoria Therapeutics Inc. - Common Stock stock logo
NEUP
Neuphoria Therapeutics Inc. - Common Stock
3.00
Buy$21.00224.07% Upside
OS Therapies Inc stock logo
OSTX
OS Therapies
3.40
Buy$18.001,039.24% Upside
PMV Pharmaceuticals, Inc. stock logo
PMVP
PMV Pharmaceuticals
3.00
Buy$5.50514.25% Upside

Current Analyst Ratings Breakdown

Latest NEUP, MURA, OSTX, and PMVP Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/15/2025
OS Therapies Inc stock logo
OSTX
OS Therapies
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00 ➝ $20.00
4/22/2025
OS Therapies Inc stock logo
OSTX
OS Therapies
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00 ➝ $20.00
4/7/2025
OS Therapies Inc stock logo
OSTX
OS Therapies
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00 ➝ $20.00
4/2/2025
OS Therapies Inc stock logo
OSTX
OS Therapies
Lake Street Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$19.00
3/31/2025
OS Therapies Inc stock logo
OSTX
OS Therapies
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00 ➝ $20.00
3/26/2025
Mural Oncology plc stock logo
MURA
Mural Oncology
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$18.00 ➝ $6.00
3/25/2025
Mural Oncology plc stock logo
MURA
Mural Oncology
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOverweight ➝ Equal Weight
3/25/2025
Mural Oncology plc stock logo
MURA
Mural Oncology
Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Outperform$18.00
3/25/2025
Mural Oncology plc stock logo
MURA
Mural Oncology
Jones Trading
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold
3/20/2025
PMV Pharmaceuticals, Inc. stock logo
PMVP
PMV Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$5.00 ➝ $5.00
3/12/2025
Mural Oncology plc stock logo
MURA
Mural Oncology
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$18.00 ➝ $18.00
(Data available from 5/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Mural Oncology plc stock logo
MURA
Mural Oncology
N/AN/AN/AN/A$15.81 per shareN/A
Neuphoria Therapeutics Inc. - Common Stock stock logo
NEUP
Neuphoria Therapeutics Inc. - Common Stock
$15.66M0.78N/AN/A$7.82 per share0.83
OS Therapies Inc stock logo
OSTX
OS Therapies
N/AN/AN/AN/AN/AN/A
PMV Pharmaceuticals, Inc. stock logo
PMVP
PMV Pharmaceuticals
N/AN/AN/AN/A$4.41 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Mural Oncology plc stock logo
MURA
Mural Oncology
-$207.45M-$7.67N/AN/AN/AN/A-70.10%-61.30%8/12/2025 (Estimated)
Neuphoria Therapeutics Inc. - Common Stock stock logo
NEUP
Neuphoria Therapeutics Inc. - Common Stock
-$15.49MN/A0.00N/AN/AN/AN/AN/AN/A
OS Therapies Inc stock logo
OSTX
OS Therapies
-$7.79M-$0.86N/AN/AN/AN/AN/A-569.57%N/A
PMV Pharmaceuticals, Inc. stock logo
PMVP
PMV Pharmaceuticals
-$68.96M-$1.18N/AN/AN/AN/A-24.20%-21.67%8/14/2025 (Estimated)

Latest NEUP, MURA, OSTX, and PMVP Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/20/2025Q3 2025
Neuphoria Therapeutics Inc. - Common Stock stock logo
NEUP
Neuphoria Therapeutics Inc. - Common Stock
-$0.47$6.55+$7.02$6.55N/A$15.00 million
5/14/2025Q1 2025
Mural Oncology plc stock logo
MURA
Mural Oncology
-$2.12-$1.93+$0.19-$1.93N/AN/A
5/9/2025Q1 2025
PMV Pharmaceuticals, Inc. stock logo
PMVP
PMV Pharmaceuticals
-$0.37-$0.34+$0.03-$0.34N/AN/A
3/11/2025Q4
Mural Oncology plc stock logo
MURA
Mural Oncology
-$1.96-$2.01-$0.05-$2.01N/AN/A
3/3/2025Q4 2024
PMV Pharmaceuticals, Inc. stock logo
PMVP
PMV Pharmaceuticals
-$0.37-$0.45-$0.08-$0.45N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Mural Oncology plc stock logo
MURA
Mural Oncology
N/AN/AN/AN/AN/A
Neuphoria Therapeutics Inc. - Common Stock stock logo
NEUP
Neuphoria Therapeutics Inc. - Common Stock
N/AN/AN/AN/AN/A
OS Therapies Inc stock logo
OSTX
OS Therapies
N/AN/AN/AN/AN/A
PMV Pharmaceuticals, Inc. stock logo
PMVP
PMV Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Mural Oncology plc stock logo
MURA
Mural Oncology
N/A
7.38
7.38
Neuphoria Therapeutics Inc. - Common Stock stock logo
NEUP
Neuphoria Therapeutics Inc. - Common Stock
N/A
2.06
3.30
OS Therapies Inc stock logo
OSTX
OS Therapies
N/A
0.76
0.76
PMV Pharmaceuticals, Inc. stock logo
PMVP
PMV Pharmaceuticals
N/A
13.98
13.98
CompanyEmployeesShares OutstandingFree FloatOptionable
Mural Oncology plc stock logo
MURA
Mural Oncology
11917.27 million17.01 millionOptionable
Neuphoria Therapeutics Inc. - Common Stock stock logo
NEUP
Neuphoria Therapeutics Inc. - Common Stock
N/A1.88 million1.75 millionN/A
OS Therapies Inc stock logo
OSTX
OS Therapies
N/A28.10 millionN/AN/A
PMV Pharmaceuticals, Inc. stock logo
PMVP
PMV Pharmaceuticals
5051.95 million47.81 millionOptionable

Recent News About These Companies

PMV Pharmaceuticals reports FY24 EPS ($1.14), consensus ($1.02)
PMV Pharmaceuticals sees cash runway to end of 2026
PMV Pharmaceuticals files $200M mixed securities shelf
PMV Pharmaceuticals upgraded to Outperform from Perform at Oppenheimer
PMV Pharmaceuticals Reports Third Quarter 2024 Financial Results
Oppenheimer Sticks to Its Hold Rating for PMV Pharmaceuticals (PMVP)
PMV Pharmaceuticals (PMVP) Gets a Buy from Craig-Hallum
PMV provides update on Phase 2, Phase 1b portions of PYNNACLE trial

New MarketBeat Followers Over Time

Media Sentiment Over Time

Mural Oncology stock logo

Mural Oncology NASDAQ:MURA

$2.64 +0.02 (+0.76%)
Closing price 05/29/2025 04:00 PM Eastern
Extended Trading
$2.68 +0.04 (+1.48%)
As of 05/29/2025 05:14 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops nemvaleukin to treat cutaneous melanoma and advanced solid tumors. The company is also developing engineered interleukin-18 and tumor-targeted interleukin-12 programs. Mural Oncology plc was incorporated in 2017 and is based in Dublin, Ireland.

Neuphoria Therapeutics Inc. - Common Stock stock logo

Neuphoria Therapeutics Inc. - Common Stock NASDAQ:NEUP

$6.48 -0.04 (-0.61%)
As of 05/29/2025 03:47 PM Eastern

Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.

OS Therapies stock logo

OS Therapies NYSE:OSTX

$1.58 -0.12 (-7.06%)
Closing price 05/29/2025 04:00 PM Eastern
Extended Trading
$1.54 -0.04 (-2.22%)
As of 05/29/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.

PMV Pharmaceuticals stock logo

PMV Pharmaceuticals NASDAQ:PMVP

$0.90 0.00 (-0.52%)
Closing price 05/29/2025 04:00 PM Eastern
Extended Trading
$0.90 +0.00 (+0.18%)
As of 05/29/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey.